Colorectal cancer (CRC) is the third leading cause of cancer deaths in men and women in the US, and it is estimated that there will be approximately 53 000 deaths due to CRC in 2023.
1 Screening for CRC is widely recommended
2-5 because, when identified early, CRC is one of the most treatable forms of cancer, with a 5-year survival rate of 90%.
6,7 In contrast, the 5-year survival rate among those diagnosed with late-stage disease is only 14%.
7 Currently, only 33% of CRCs are diagnosed at the earliest stage.
1 Individuals with an abnormal result of a stool-based screening test (SBT) must receive timely follow-up with a colonoscopy because patients experience increased negative clinical outcomes, such as later-stage diagnosis, when follow-up after an abnormal SBT result is delayed by more than 6 to 12 months.
8-10 Diagnosis at an early stage will reduce neoplastic progression of disease
8-10 and therefore increase the possibility of curative treatment.
9 It follows that early diagnosis may also decrease downstream complications, improve outcomes, and minimize costs to the patient and the health care system.
11 Further, early diagnosis helps reduce racial and ethnic disparities in outcomes: when CRC is diagnosed at a localized stage, survival rates are comparable across racial and ethnic groups.
12